Versatile Bioadhesives

Solicitation ARPA-H 02 is a Total Small Business Set-Aside under the ARPA-H Small Business Program (SBIR/STTR) focused on developing next-generation bioadhesive platforms. The objective is to create biocompatible, reversible, and strong tissue adhesives capable of sealing and repairing tissues in challenging clinical environments, such as wet or bloody conditions, while potentially delivering biologics or small molecules. These solutions aim to improve patient outcomes in hemostasis, leak prevention, and device fixation. The program is structured in phases, with Phase I lasting up to 24 months and Phase II or Sequential Phase II lasting up to 36 months. Applicants must submit a solution summary, key personnel worksheet, and a cost proposal, with specific funding available for Technical Assistance for Biologic Applications (TABA) up to 6,500 dollars for Phase I and 50,000 dollars for Phase II. Evaluation is based on technical merit, novelty, team expertise, and the path to impact, utilizing the ARPA-H Heilmeier Questions to assess the health problem and the transformative nature of the solution. Awardees are required to provide a GANTT chart and a Task Description Document to monitor progress. The contract incorporates various FAR and HHSAR clauses, including strict adherence to Revised 508 Standards for all information and communication technology deliverables and electronic payment processing via the Department of Treasury Invoice Processing Platform.